Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 38


Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas.

Chinyengetere F, Sekula DJ, Lu Y, Giustini AJ, Sanglikar A, Kawakami M, Ma T, Burkett SS, Eisenberg BL, Wells WA, Hoopes PJ, Demicco EG, Lazar AJ, Torres KE, Memoli V, Freemantle SJ, Dmitrovsky E.

BMC Cancer. 2015 Nov 10;15:886. doi: 10.1186/s12885-015-1883-8.


Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression.

Teicher BA, Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Connelly J, Harris E, Monks A, Morris J.

Mol Cancer Ther. 2015 Nov;14(11):2452-62. doi: 10.1158/1535-7163.MCT-15-0074. Epub 2015 Sep 8.


MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics.

Varshney J, Subramanian S.

Front Mol Biosci. 2015 Jun 17;2:31. doi: 10.3389/fmolb.2015.00031. eCollection 2015. Review.


Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis.

Eisinger-Mathason TS, Mucaj V, Biju KM, Nakazawa MS, Gohil M, Cash TP, Yoon SS, Skuli N, Park KM, Gerecht S, Simon MC.

Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):E3402-11. doi: 10.1073/pnas.1420005112. Epub 2015 Jun 15.


Comparison of Perioperative Radiation Therapy and Surgery Versus Surgery Alone in 204 Patients With Primary Retroperitoneal Sarcoma: A Retrospective 2-Institution Study.

Kelly KJ, Yoon SS, Kuk D, Qin LX, Dukleska K, Chang KK, Chen YL, Delaney TF, Brennan MF, Singer S.

Ann Surg. 2015 Jul;262(1):156-62. doi: 10.1097/SLA.0000000000001063.


Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets.

Movva S, Wen W, Chen W, Millis SZ, Gatalica Z, Reddy S, von Mehren M, Van Tine BA.

Oncotarget. 2015 May 20;6(14):12234-47.


Down-regulated E-cadherin expression is associated with poor five-year overall survival in bone and soft tissue sarcoma: results of a meta-analysis.

Wang N, He YL, Pang LJ, Zou H, Liu CX, Zhao J, Hu JM, Zhang WJ, Qi Y, Li F.

PLoS One. 2015 Mar 30;10(3):e0121448. doi: 10.1371/journal.pone.0121448. eCollection 2015.


Targeted therapy in sarcomas other than GIST tumors.

Sborov D, Chen JL.

J Surg Oncol. 2015 Apr;111(5):632-40. doi: 10.1002/jso.23802. Epub 2014 Oct 20. Review.


Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma.

Yang J, Annala M, Ji P, Wang G, Zheng H, Codgell D, Du X, Fang Z, Sun B, Nykter M, Chen K, Zhang W.

J Hematol Oncol. 2014 Oct 10;7:76. doi: 10.1186/s13045-014-0076-2.


PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.

Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, Zhu S, Cao Z, Liang Y, Sboner A, Tap WD, Fletcher JA, Huberman KH, Qin LX, Viale A, Singer S, Zheng D, Berger MF, Chen Y, Antonescu CR, Chi P.

Nat Genet. 2014 Nov;46(11):1227-32. doi: 10.1038/ng.3095. Epub 2014 Sep 21.


Cellular immunotherapy for pediatric solid tumors.

Hegde M, Moll AJ, Byrd TT, Louis CU, Ahmed N.

Cytotherapy. 2015 Jan;17(1):3-17. doi: 10.1016/j.jcyt.2014.05.019. Epub 2014 Jul 28. Review.


Changing histopathological diagnostics by genome-based tumor classification.

Kloth M, Buettner R.

Genes (Basel). 2014 May 28;5(2):444-59. doi: 10.3390/genes5020444.


Dystrophin is a tumor suppressor in human cancers with myogenic programs.

Wang Y, Marino-Enriquez A, Bennett RR, Zhu M, Shen Y, Eilers G, Lee JC, Henze J, Fletcher BS, Gu Z, Fox EA, Antonescu CR, Fletcher CD, Guo X, Raut CP, Demetri GD, van de Rijn M, Ordog T, Kunkel LM, Fletcher JA.

Nat Genet. 2014 Jun;46(6):601-6. doi: 10.1038/ng.2974. Epub 2014 May 4.


Development of genetically flexible mouse models of sarcoma using RCAS-TVA mediated gene delivery.

Kabaroff L, Gupta A, Menezes S, Babichev Y, Kandel RC, Swallow CJ, Dickson BC, Gladdy RA.

PLoS One. 2014 Apr 14;9(4):e94817. doi: 10.1371/journal.pone.0094817. eCollection 2014.


TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.

Koelsche C, Renner M, Hartmann W, Brandt R, Lehner B, Waldburger N, Alldinger I, Schmitt T, Egerer G, Penzel R, Wardelmann E, Schirmacher P, von Deimling A, Mechtersheimer G.

J Exp Clin Cancer Res. 2014 Apr 11;33:33. doi: 10.1186/1756-9966-33-33.


Bioenergetic properties of human sarcoma cells help define sensitivity to metabolic inhibitors.

Issaq SH, Teicher BA, Monks A.

Cell Cycle. 2014;13(7):1152-61. doi: 10.4161/cc.28010. Epub 2014 Feb 10.


Chromothripsis-like patterns are recurring but heterogeneously distributed features in a survey of 22,347 cancer genome screens.

Cai H, Kumar N, Bagheri HC, von Mering C, Robinson MD, Baudis M.

BMC Genomics. 2014 Jan 29;15:82. doi: 10.1186/1471-2164-15-82.


ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma.

Wiles ET, Bell R, Thomas D, Beckerle M, Lessnick SL.

Genes Cancer. 2013 Nov;4(11-12):486-500. doi: 10.1177/1947601913506115.


Hypoxia signaling--license to metastasize.

Vanharanta S, Massagué J.

Cancer Discov. 2013 Oct;3(10):1103-4. doi: 10.1158/2159-8290.CD-13-0481.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk